Kawamura Y, Shimomura A, Taniyama T, Hirai H, Hashimoto K, Honda Y
Oncol Lett. 2025; 29(3):136.
PMID: 39839606
PMC: 11747951.
DOI: 10.3892/ol.2025.14882.
Alan O, Bulbul M, Enlice M, Mandel N
Immunotherapy. 2025; 17(1):11-17.
PMID: 39812468
PMC: 11834416.
DOI: 10.1080/1750743X.2025.2451604.
Wu Y, Sun X, Kang K, Yang Y, Li H, Zhao A
J Hematol Oncol. 2024; 17(1):106.
PMID: 39511607
PMC: 11542428.
DOI: 10.1186/s13045-024-01621-x.
Patton L, Monteith B, Heffernan P, Herzinger T, Wilson B
Front Oncol. 2024; 14:1394543.
PMID: 38919527
PMC: 11196757.
DOI: 10.3389/fonc.2024.1394543.
Ota H, Munechika M, Tobino K, Uchida K, Muarakami Y
Cureus. 2024; 16(4):e58253.
PMID: 38745801
PMC: 11091938.
DOI: 10.7759/cureus.58253.
Hemophagocytic lymphohistiocytosis following pembrolizumab and bevacizumab combination therapy for cervical cancer: a case report and systematic review.
Zhai C, Jin X, You L, Yan N, Dong J, Qiao S
BMC Geriatr. 2024; 24(1):32.
PMID: 38191289
PMC: 10773023.
DOI: 10.1186/s12877-023-04625-3.
Diagnosis and Management of Adult Malignancy-Associated Hemophagocytic Lymphohistiocytosis.
Lee J, Logan A
Cancers (Basel). 2023; 15(6).
PMID: 36980725
PMC: 10046521.
DOI: 10.3390/cancers15061839.
Systemic inflammatory syndromes as life-threatening side effects of immune checkpoint inhibitors: case report and systematic review of the literature.
Liu L, Skribek M, Harmenberg U, Gerling M
J Immunother Cancer. 2023; 11(3).
PMID: 36878533
PMC: 9990684.
DOI: 10.1136/jitc-2022-005841.
Treatment-related hemophagocytic lymphohistiocytosis due to atezolizumab: a case report and review of the literature.
Rubio-Perez J, Rodriguez-Perez A, Diaz-Blazquez M, Moreno-Garcia V, Domine-Gomez M
J Med Case Rep. 2022; 16(1):365.
PMID: 36195892
PMC: 9531226.
DOI: 10.1186/s13256-022-03585-3.
Immune-Related Uncommon Adverse Events in Patients with Cancer Treated with Immunotherapy.
Albarran-Artahona V, Laguna J, Gorria T, Torres-Jimenez J, Pascal M, Mezquita L
Diagnostics (Basel). 2022; 12(9).
PMID: 36140493
PMC: 9498261.
DOI: 10.3390/diagnostics12092091.
Hemophagocytic lymphohistiocytosis in two patients following treatment with pembrolizumab: two case reports and a literature review.
Wei Y, He W, Sun W, Wu C, Ren D, Wang X
Transl Cancer Res. 2022; 11(8):2960-2966.
PMID: 36093533
PMC: 9459512.
DOI: 10.21037/tcr-22-154.
Haemophagocytic lymphohistiocytosis as a complication of combination anti-PD-1 and anti-CTLA-4 checkpoint inhibitor immunotherapy for metastatic melanoma, and the outcome of rechallenge with single-agent anti-PD-1 immunotherapy.
Holmes Z, Courtney A, Hiong A
BMJ Case Rep. 2022; 15(8).
PMID: 35948362
PMC: 9379485.
DOI: 10.1136/bcr-2022-251052.
Secondary hemophagocytic lymphohistiocytosis due to nivolumab/ipilimumab in a renal cell cancer patient-A case report.
Masood A, Wahab A, Clifford T, Weaver E, Ehsan H, El Ayass W
Clin Case Rep. 2021; 9(12):e05184.
PMID: 34917381
PMC: 8645178.
DOI: 10.1002/ccr3.5184.
Diagnosis and Management of Hematological Adverse Events Induced by Immune Checkpoint Inhibitors: A Systematic Review.
Omar N, El-Fass K, Abushouk A, Elbaghdady N, Barakat A, Noreldin A
Front Immunol. 2020; 11:1354.
PMID: 33193289
PMC: 7640759.
DOI: 10.3389/fimmu.2020.01354.
Phase I Clinical Trial of Combination Propranolol and Pembrolizumab in Locally Advanced and Metastatic Melanoma: Safety, Tolerability, and Preliminary Evidence of Antitumor Activity.
Gandhi S, Pandey M, Attwood K, Ji W, Witkiewicz A, Knudsen E
Clin Cancer Res. 2020; 27(1):87-95.
PMID: 33127652
PMC: 7785669.
DOI: 10.1158/1078-0432.CCR-20-2381.
Hemophagocytic Lymphohistiocytosis Secondary to PD-1 and IDO Inhibition in a Patient with Refractory Glioblastoma.
Thummalapalli R, Heumann T, Stein J, Khan S, Priemer D, Duffield A
Case Rep Oncol. 2020; 13(2):508-514.
PMID: 32518546
PMC: 7265705.
DOI: 10.1159/000507281.
A case of pembrolizumab-induced hemophagocytic lymphohistiocytosis successfully treated with pulse glucocorticoid therapy.
Takahashi H, Koiwa T, Fujita A, Suzuki T, Tagashira A, Iwasaki Y
Respir Med Case Rep. 2020; 30:101097.
PMID: 32489850
PMC: 7260580.
DOI: 10.1016/j.rmcr.2020.101097.
Pembrolizumab-induced Hemophagocytic Lymphohistiocytosis: an immunotherapeutic challenge.
Kalmuk J, Puchalla J, Feng G, Giri A, Kaczmar J
Cancers Head Neck. 2020; 5:3.
PMID: 32025343
PMC: 6996173.
DOI: 10.1186/s41199-020-0050-3.
Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor-related hematological adverse events.
Zhuang J, Du J, Guo X, Zhou J, Duan L, Qiu W
Thorac Cancer. 2020; 11(3):799-804.
PMID: 32017466
PMC: 7049514.
DOI: 10.1111/1759-7714.13281.
Hemophagocytic Lymphohistiocytosis in a Patient with Rheumatoid Arthritis on Pembrolizumab for Lung Adenocarcinoma.
Akagi Y, Awano N, Inomata M, Kuse N, Tone M, Yoshimura H
Intern Med. 2020; 59(8):1075-1080.
PMID: 32009093
PMC: 7205536.
DOI: 10.2169/internalmedicine.3889-19.
